Analysis of D7S486 in Primary Gastric Cancer and Evaluation of TESTIN As a Candidate Tumor Suppressor Gene.

Jun Xia,Daniel Y. Weng,Hong Ma,Y. Chen,Wenhua Huang,Kathy Pan

DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.4129

IF: 45.3

2010-01-01

Journal of Clinical Oncology

Abstract:4129 Background: Gastric cancer (GC) is one of the most common malignancies in Asia. High frequency of loss of heterozygosity (LOH) was found on D7S486 in primary GC, suggesting some tumor suppressor genes (TSGs) harbored in this region. Methods: To determine what GC-associated TSGs were located in this region, we analyzed the LOH at D7S486 in 105 patients with primary GC through a high-flux single nucleotide polymorphism (SNP) scan by self-made SNP microarray technology. To clarify the role of TESTIN (TES) in GC, we examined its expression in primary GC and its relationship to clinicopathological characteristics and prognosis. In addition, we also studied the effect of TES overexpression on the proliferation of several GC cell lines. Furthermore, mutation and methylation analysis were performed to explore its possible mechanisms of inactivation in GC. Results: We discovered five candidate genes (ST7Å, FOXP2Å, MDFIC, TES and CAV1) corresponding to SNPs whose frequencies of LOH were higher than 30%. However, only TES showed the potential to be a TSG associated with GC. In primary GC, TES showed a significant low expression in both transcriptive and translational level when compared to adjacent nontumorous tissues. In addition, down regulation of TES was shown to correlate with differentiation and prognosis. We also determined the inhibitory effect of TES overexpression on the growth of three GC cell lines. Methylation analysis showed that hypermethylation of TES promoter was a frequent event in primary GC samples and GC cell lines in which TES expression was down regulated. However, no specific gene mutation was observed in the coding region of the TES gene. Conclusions: Collectively, these results support the role of TES as a TSG in gastric carcinogenesis and that TES is inactivated primarily by transcriptional silencing resulting from CpG island methylation rather than by gene mutation. No significant financial relationships to disclose.